Noble Partners
Latest statistics and disclosures from Noble Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Us Natural Gas Fd Etf, GLNG, Ariad Pharmaceuticals, Jazz Pharmaceuticals, Pacific Ethanol, and represent 52.21% of Noble Partners's stock portfolio.
- Added to shares of these 10 stocks: GLNG, Pacific Ethanol, Jazz Pharmaceuticals, Celgene Corporation, NPS Pharmaceuticals, Ariad Pharmaceuticals, JNJ, VRTX, Optimer Pharmaceuticals, PODD.
- Started 11 new stock positions in JNJ, NPS Pharmaceuticals, Optimer Pharmaceuticals, Inhibitex, CYH, Pacific Ethanol, GPRE, Celgene Corporation, VRTX, PODD. GLNG.
- Reduced shares in these 10 stocks: TSLA, Us Natural Gas Fd Etf, Golar Lng Partners Lp unit, Akorn, Cubist Pharmaceuticals, Northgate Minerals, Salix Pharmaceuticals, WellPoint, Medicis Pharmaceutical Corporation, Perrigo Company.
- Sold out of its positions in Banro Corp, BioSante Pharmaceuticals, Cubist Pharmaceuticals, Dendreon Corporation, Human Genome Sciences, Medicis Pharmaceutical Corporation, Northgate Minerals, Salix Pharmaceuticals, TSLA, WellPoint. Golar Lng Partners Lp unit.
- Noble Partners was a net seller of stock by $-7.3M.
- Noble Partners has $14M in assets under management (AUM), dropping by -38.75%.
- Central Index Key (CIK): 0001350882
Portfolio Holdings for Noble Partners
Noble Partners holds 21 positions in its portfolio as reported in the December 2011 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Us Natural Gas Fd Etf | 20.5 | $2.9M | -50% | 450k | 6.46 |
|
| Golar Lng (GLNG) | 10.8 | $1.5M | NEW | 50k | 30.66 |
|
| Ariad Pharmaceuticals | 7.3 | $1.0M | +112% | 85k | 12.25 |
|
| Jazz Pharmaceuticals | 6.8 | $966k | +257% | 25k | 38.64 |
|
| Pacific Ethanol | 6.7 | $954k | NEW | 900k | 1.06 |
|
| Allergan | 6.2 | $877k | -9% | 10k | 87.70 |
|
| Elan Corporation | 4.8 | $687k | +25% | 50k | 13.74 |
|
| Celgene Corporation | 4.8 | $676k | NEW | 10k | 67.60 |
|
| NPS Pharmaceuticals | 4.0 | $560k | NEW | 85k | 6.59 |
|
| Akorn | 3.9 | $556k | -61% | 50k | 11.12 |
|
| Johnson & Johnson (JNJ) | 3.7 | $525k | NEW | 8.0k | 65.62 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 3.5 | $498k | NEW | 15k | 33.20 |
|
| Optimer Pharmaceuticals | 3.5 | $490k | NEW | 40k | 12.25 |
|
| Amarin Corporation (AMRN) | 3.2 | $449k | +100% | 60k | 7.48 |
|
| Insulet Corporation (PODD) | 2.7 | $377k | NEW | 20k | 18.85 |
|
| Inhibitex | 2.3 | $328k | NEW | 30k | 10.93 |
|
| Perrigo Company | 2.1 | $292k | -62% | 3.0k | 97.33 |
|
| Green Plains Renewable Energy (GPRE) | 1.4 | $195k | NEW | 20k | 9.75 |
|
| Community Health Systems (CYH) | 1.2 | $175k | NEW | 10k | 17.50 |
|
| Cardiome Pharma Corp | 0.5 | $69k | -72% | 26k | 2.64 |
|
| ACADIA Pharmaceuticals (ACAD) | 0.2 | $22k | 20k | 1.10 |
|
Past Filings by Noble Partners
SEC 13F filings are viewable for Noble Partners going back to 2010
- Noble Partners 2011 Q4 filed Feb. 14, 2012
- Noble Partners 2011 Q3 filed Nov. 14, 2011
- Noble Partners 2011 Q2 filed Aug. 15, 2011
- Noble Partners 2011 Q1 filed May 16, 2011
- Noble Partners 2010 Q4 filed Feb. 14, 2011